回生口服液联合化疗治疗晚期肺癌的Meta分析

Clinical Efficacy of Huisheng Oral Liquid Combined with Chemotherapy in the Treatment of Lung Cancer:a Meta Analysis

目的应用Meta分析评价回生口服液联合化疗与单纯化疗相比在中晚期肺癌患者治疗中的优越性和临床意义。方法检索中国期刊全文数据库（CNKI）、中国生物医学期刊数据库（CBM）、万方知识数据服务平台、中文期刊全文数据库（VIP）、Pubmed数据库、MEDLINE和Embase等电子数据库,检索时间截至2015年3月20日,纳入回生口服液联合化疗治疗中晚期肺癌的随机对照研究,用修改后的Jadad量表评价纳入研究的质量,应用Rev Man5.3软件进行数据分析。结果共纳入10个随机对照临床试验,包括711例患者。纳入文献均为低质量研究。Meta分析结果表明：与对照组比较,回生口服液联合化疗可以提高中晚期肺癌患者的近期疗效[（P=0.001）,OR=1.49,95%CI（1.10,2.02）],改善患者的生命质量[（P〈0.0001）,OR=2.64,95%CI（1.62,4.31）],Ⅲ~Ⅳ级白细胞减少的发生率[（P〈0.00001）,OR=0.18,95%CI（0.09,0.35）],减轻消化道反应[（P=0.009）,OR=0.39,95%CI（0.19,0.79）]。结论回生口服液联合化疗治疗中晚期肺癌患者具有一定的减毒增效作用。

Objective To evaluate the advantage and clinical value of Huisheng Oral Liquid combined with chemotherapy in the treatment of lung cancer.Methods We searched the electronic databases of CBM,CNKI,VIP, Wangfang,Pubmed database,MEDLINE and Embase for randomized controlled trials（RCTs） that connect with Huisheng Oral Liquid combined with chemotherapy in the treatment of lung cancer,the date before March 20,2015.Quality of the included RCTs was assessed by revised Jadad scoring.And Meta-analyses were performed by using Rev Man5.3 software.Result Ten RCTs involving 711 patients were included in the study.The quality of all studies was in low quality.The results of Meta-analyses showed that Huisheng Oral Liquid combined with chemotherapy for lung cancer, compared with control groups,Could increase the recent curative effect[P=0.001,OR=1.49,95%CI（1.10,2.02）]and improve the quality of live（QOL）[P〈0.0001,OR=2.64,95%CI（1.62,4.31）],decrease the incidence rate of hypoleucocytosis in stage Ⅲ-Ⅳ[P〈0.00001,OR=0.18,95%CI（0.09,0.35）],decrease the gastrointestinal reaction[P=0.009, OR=0.39, 95%CI（0.19,0.79）]. Conclusion The results of Meta-analysis indicate that Huisheng Oral Liquid combined with chemotherapy may have therapeutic effects in the treatment of lung cancer.